本研究旨在瞭解精神分裂症病患服用抗精神病藥物的經驗。研究結果可作為護理人員了解個案服藥意願並提供必要的幫助。研究對象採立意取樣，選取滿20歲、確診精神分裂症5年(含)以上、至少連續或總計達一年有服用一種抗精神病藥物，且訪談期間仍繼續服用、整體評估量表總分60分(含)以上者。資料收集為非結構式一對一訪談方式，資料飽和時共訪談13位個案。資料分析採Colaizzi分析法。研究結果呈現與藥物共舞的經驗，包含三個主題及六個次主題，分別為共舞前排斥服藥的經驗 (生理及心理的服藥受苦經驗)、共舞中與服藥對話的經驗 (共舞中與服藥對話的搖擺及發現經驗)、共舞後與服藥融合的經驗 (舞出改變及服藥意義的經驗)。個案會因服藥後病情穩定，引發想靠毅力或認為已痊癒不需再服藥而減藥或停藥，使疾病復發再次住院治療，造成個案徘徊在這三個服藥歷程中。本研究亦發現影響個案與服藥融合經驗的主要因素包含藥物副作用、無病識感、服藥遵從性低、低自尊、社會烙印等。然而，家人、醫療人員及宗教等支持系統能提升個案接受服藥治療。本研究結果提供大家對精神分裂症病患服用抗精神病藥物經驗的了解，以期在病人服藥歷程的不同階段，給予個別性協助提升照護品質。
This study was undertaken to understand the experiences of taking neuroleptic medicine for patients with schizophrenia. The result can be referred for nurses to understand the clients’ compliance of taking medicine and provide necessary assistance. Purposive sampling was used in this study to choose these people who were over 20-year-old, diagnosis of schizophrenia more than five years, taking more than one kind of neuroleptic medicine over one year at least, and GAF ≧ 60. Non-structured one-to-one interviews were used for data collection. When theoretical saturation was achieved, 13 patients were interviewed. Narrative data will be analyzed according to Colaizzi’s method. The result shows the experiences of patients who dance with medicine, including three themes and six sub-themes—before dancing with medicine: the experiences of refusing to take medicine (the physical and psychical suffering experiences of taking medicine), dancing with medicine: the experiences of adjusting to take medicine (the swing and discovery experiences of adjusting to take medicine while dancing with medicine), and after dancing with medicine: the experiences of coexisting with take medicine (the experiences of change and the meaning of take medicine). After taking medicine, the clients would be stable and then they stop taking medicine as they might think they were healed; however, they would relapse and rehospitalize again. It makes clients move around these three stages of taking medicine. This study also found the main factors which affect clients and the experiences of coexisting with take medicine include side-effects, no insight, low compliance with medicine, low self-esteem, and social stigma. Nevertheless, the supportive system from families, medical staff and religion could make clients accept take medicine treatment. The result of this study could be referred to understand the experiences of taking neuroleptic medicine for patients with schizophrenia and provide individual assistance for patients in different stages of taking medicine to improve the quality of care.
